Underrecognized peripheral arterial disease in patients with acute coronary syndrome: Prevalence of traditional and emergent cardiovascular risk factors;Enfermedad arterial periférica desconocida en pacientes con síndrome coronario agudo: Prevalencia y patrón diferencial de los factores de riesgo cardiovascular tradicionales y emergentes

Revista Espanola de Cardiologia

Volumn 58, Issue 12, 2005, Pages 1403-1410

  Huelmos, Ana ^a   Jiménez, Julia ^a   Guijarro, Carlos ^a   Belinchón, Juan C ^a   Puras, Enrique ^a   Sánchez, Carmen ^a   Casas, María L ^a   López Bescos, Lorenzo ^a   Mesa, Nieves ^a   Anglada, Isabel González ^a   Luján, Salvador ^a   Tarín, Nieves ^a   Melgares, Lidia ^a   Barriga, Francisco J ^a   Fernández, Francisco J ^a   Treviño, Miguel A ^a   Tolón, Rosa M ^a  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

Author keywords

Cardiovascular risk factors; Coronary disease; Peripheral arterial disease

Indexed keywords

AMYLOID A PROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B100; C REACTIVE PROTEIN; FIBRINOGEN; HOMOCYSTEINE; LIPOPROTEIN A; TOBACCO SMOKE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANKLE BRACHIAL INDEX; ARTERY DISEASE; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES CONTROL; DIAGNOSTIC ERROR; ENVIRONMENTAL EXPOSURE; GENOTYPE; HOSPITAL ADMISSION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MICROALBUMINURIA; PREDICTION; PREVALENCE; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PULSE PRESSURE; QUANTITATIVE ANALYSIS; RISK FACTOR; STATISTICAL ANALYSIS;

EID: 32044469375     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0300-8932(05)74070-7     Document Type: Article

References (46)

1. Criqui MH, Denenberg JO. The generalized nature of atherosclerosis: how peripheral arterial disease may predict adverse events from coronary artery disease. Vasc Med. 1998;3:241-5.
2. Eagle KA, Rihal CS, Foster ED, Mickel MC, Gersh BJ. Long-term survival in patients with coronary artery disease: importance of peripheral vascular disease. The Coronary Artery Surgery Study (CASS) Investigators. J Am Coll Cardiol. 1994;23:1091-5.
3. Magovern JA, Sakert T, Magovern GJ, Benckart DH, Burkholder JA, Liebler GA, et al. A model that predicts morbidity and mortality after coronary artery bypass graft surgery. J Am Coll Cardiol. 1996;28:1147-53.
4. Krumholz HM, Chen J, Chen YT, Wang Y, Radford MJ. Predicting one-year mortality among elderly survivors of hospitalization for an acute myocardial infarction: results from the Cooperative Cardiovascular Project. J Am Coll Cardiol. 2001;38:453-9.
5. López Bescós L, Arós Borau F, Lidón Corbi RM, Cequier Fillat A, Bueno H, Alonso JJ, et al. Actualización (2002) de las Guías de Práctica Clínica de la Sociedad Española de Cardiología en angina inestable/infarto sin elevación del segmento ST. Rev Esp Cardiol. 2002;55:631-42.
6. Bertrand ME, Simoons ML, Fox KA, Wallentin LC, Hamm CW, McFadden E, et al. Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation; recommendations of the Task Force of the European Society of Cardiology. Eur Heart J. 2000;21:1406-32.
7. Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286: 1317-24.
8. Grant EG, Benson CB, Moneta GL, Alexandrov AV, Baker JD, Bluth EI, et al. Carotid artery stenosis: grayscale and Doppler ultrasound diagnosis - Society of Radiologists in Ultrasound consensus conference. Ultrasound Q. 2003;19:190-8.
9. Rifai N, Joubran R, Yu H, Asmi M, Jouma M. Inflammatory markers in men with angiographically documented coronary heart disease. Clin Chem. 1999;45:1967-73.
10. Lahoz C, Mostaza JM. Marcadores genéticos asociados con enfermedad cardíaca isquémica. Med Clin (Barc). 1999; 113:463-70.
11. Grewal J, Chan S, Frohlich J, Mancini GB. Assessment of novel risk factors in patients at low risk for cardiovascular events based on Framingham risk stratification. Clin Invest Med. 2003;26:158-65.
12. Hackam DG, Anand SS. Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. JAMA. 2003;290:932-40.
13. Nikolsky E, Mehran R, Mintz GS, Dangas GD, Lansky AJ, Aymong ED, et al. Impact of symptomatic peripheral arterial disease on 1-year mortality in patients undergoing percutaneous coronary interventions. J Endovas Ther. 2004;11:60-70.
14. Narins CR, Zareba W, Moss AJ, Marder VJ, Ridker PM, Krone RJ, et al. Relationship between intermittent claudication, inflammation, thrombosis, and recurrent cardiac events among survivors of myocardial infarction. Arch Intern Med. 2004;164:440-6.
15. Ness J, Aronow WS, Ahn C. Prevalence of coronary artery disease, ischemic stroke, and symptomatic peripheral arterial disease and of associated risk factors in older men and women with and without diabetes mellitus. J Am Geriatr Sec. 1999;47:1255-6.
16. Atmer B, Jogestrand T, Laska J, Lund F. Peripheral artery disease in patients with coronary artery disease. Int Angiol. 1995;14:89-93.
17. Ciccone M, Di Noia D, Di Michele L, Corriero F, Di Biase M, Biasco MG, et al. The incidence of asymptomatic extracoronary atherosclerosis in patients with coronary atherosclerosis. Int Angiol. 1993;12:25-8.
18. Moussa I, Mehran R, Roubin GS, Iyer S, Limpijankit T, Losquadro M, et al. Detection of peripheral arterial disease in patients presenting for coronary angiography and/or intervention patients study (PIPS) (abstract). J Am Coll Cardiol. 2003;41:113.
19. Bowlin SJ, Medalie JH, Flocke SA, Zyzanski SJ, Yaari S, Goldbourt U. Intermittent claudication in 8343 men and 21-year specific mortality follow-up. Ann Epidemiol. 1997;7:180-7.
20. Muluk SC, Muluk VS, Kelley ME, Whittle JC, Tierney JA, Webster MW, et al. Outcome events in patients with claudication: a 15-year study in 2777 patients. J Vasc Surg. 2001;33:251-8.
21. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326: 381-6.
22. Dawson I, Van Bockel JH, Brand R. Late nonfatal and fatal cardiac events after infrainguinal bypass for femoropopliteal occlusive disease during a thirty-one-year period. J Vasc Surg. 1993;18:249-60.
23. Khoury Z, Schwartz R, Gottlieb S, Chenzbraun A, Stern S, Keren A. Relation of coronary artery disease to atherosclerotic disease in the aorta, carotid, and femoral arteries evaluated by ultrasound. Am J Cardiol. 1997;80:1429-33.
24. Zimarino M, Cappelletti L, Venarucci V, Gallina S, Scarpignato M, Acciai N, et al. Age-dependence of risk factors for carotid stenosis: an observational study among candidates for coronary arteriography. Atherosclerosis. 2001;159:165-73.
25. Luján S, Puras L, López-Bescos L, Belinchón JC, Gutiérrez M, Guijarro C. Occult vascular lesions in patients with atherothrobotic events: the AIRVAG Cohort. Eur J Vasc Endovasc Surg. 2005;30:57-62.
26. Tseng CH. Pulse pressure as a risk factor for peripheral vascular disease in type 2 diabetic patients. Clin Exp Hypertens. 2003;25: 475-85.
27. Brevetti F, Piscione F, Sivestro A, Galasso G, Di Donato A, Oliva G, et al. Increased inflammatory status and higher prevalence of three-vessel coronary artery disease in patients with concomitant coronary and peripheral atherosclerosis. Thromb Haemost. 2003;89:1058-63.
28. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet. 1997;349:462-6.
29. Bickel C, Rupprecht HJ, Blankenberg S, Espiniola-Klein C, Schlitt A, Rippin G, et al. Relation of markers of inflammation (C-reactive protein, fibrinogen, von Willebrand factor, and leukocyte count) and statin therapy to long-term mortality in patients with angiographically proven coronary artery disease. Am J Cardiol. 2002;89:901-8.
30. Zebrack JS, Anderson JL, Maycock CA, Home BD, Bair TL, Muhlestein JB. Intermountain Heart Collaborative (IHC) Study Group. Usefulness of high-sensitivity C-reactive protein in predicting long-term risk of death or acute myocardial infarction in patients with unstable or stable angina pectoris or acute myocardial infarction. Am J Cardiol. 2002;89:145-9.
31. Morrow DA, Rifai N, Antman EM, Weiner DL, McCabe CH, Cannon CP, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in myocardial infarction. J Am Coll Cardiol. 1998;31:1460-5.
32. Rebuzzi AG, Quaranta G, Liuzzo G, Caligiuri G, Lanza GA, Gallimore JR, et al. Incremental prognostic value of serum levels of troponin T and C-reactive protein on admission in patients with unstable angina pectoris. Am J Cardiol. 1998;82:715-9.
33. Chew DP, Bhatt DL, Robbins MA, Penn MS, Schneider JP, Lauer MS, et al. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation. 2001;104:992-7.
34. Walter DH, Fichtlscherer S, Britten MB, Rosin P, Auch-Schwelk W, Schachinger V, et al. Statin therapy, inflammation and recurrent coronary events in patients following coronary stent implantation. J Am Coll Cardiol. 2001;38:2006-12.
35. Zhou YF, Csako G, Grayston JT, Wang SP, Yu ZX, Shou M, et al. Lack of association of restenosis following coronary angioplasty with elevated C-reactive protein levels or seropositivity to Chlamydia pneumoniae. Am J Cardiol. 1999;84:595-8.
36. Di Napoli M, Papa F, Bocola V. C-reactive protein in ischemic stroke: an independent prognostic factor. Stroke. 2001;32:917-24.
37. Rossi E, Biasucci LM, Citterio F, Pelliccioni S, Monaco C, Ginnetti F, et al. Risk of myocardial infaretion and angina in patients with severe peripheral vascular disease: predictive role of C-reactive protein. Circulation. 2002;105:800-3.
38. Arroyo-Espliguero R, Avanzas P, Kaski JC. Enfermedad cardiovascular aterosclerótica: la utilidad de la proteína C reactiva en la identificación de la placa «vulnerable» y del paciente «vulnerable». Rev Esp Cardiol. 2004;57:375-8.
39. Sanchís J, Bodí V, Llácer A, Facila L, Martínez-Brotons A, Insa L, et al. Relación de los valores de proteína C reactiva con los hallazgos angiográficos y los marcadores de necrosis en el síndrome coronario agudo sin elevación del segmento ST. Rev Esp Cardiol. 2004;57:382-7.
40. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511.
41. Stanger O, Herrmann W, Pietrzik K, Fowler B, Geisel J, Dierkes J, et al; DACH-LIGA Homocystein e.V. DACH-LIGA homocystein (german, austrian and swiss homocysteine society): consensus paper on the rational clinical use of homocysteine, folic acid and B-vitamins in cardiovascular and thrombotic diseases: guidelines and recommendations. Clin Chem Lab Med. 2003;41:1392-403.
42. Ciccarone E, Di Castelnuovo A, Assanelli D, Archetti S, Ruggeri G, Salcuni N, et al. GENDIABE Investigators. Homocysteine levels are associated with the severity of peripheral arterial disease in Type 2 diabetic patients. J Thromb Haemost. 2003;1:2540-7.
43. Darius H, Pittrow D, Haberl R, Trampisch HJ, Schuster A, Lange S, et al. Are elevated homocysteine plasma levels related to peripheral arterial disease? Results from a cross-sectional study of 6880 primary care patients. Eur J Clin Invest. 2003;33:751-7.
44. Wilson PW, Schaefer EJ, Larson MG, Ordovas JM. Apolipoprotein E alleles and risk of coronary disease. A meta-analysis. Arterioscler Thromb Vasc Biol. 1996;16:1250-5.
45. Staessen JA, Wang JG, Ginocchio G, Petrov V, Saavedra AP, Soubrier F, et al. The deletion/insertion polymorphism of the angiotensin converting enzyme gene and cardiovascular-renal risk. J Hypertens. 1997;15:1579-92.
46. Beilby JP, Hunt CC, Palmer LJ, Chapman CM, Burley JP, McQuillan BM, et al. Perth carotid ultrasound disease assessment study. Apolipoprotein E gene polymorphisms are associated with carotid plaque formation but not with intima-media wall thickening: results from the Perth Carotid Ultrasound Disease Assessment Study (CUDAS). Stroke. 2003;34:869-74.